Suzhou Siran Biotechnology Co. Ltd. (SiranBio) has entered a worldwide exclusive license agreement with GSK (excluding mainland China, Hong Kong, Macau and Taiwan) for SA030, a potential first-in-disease, long-acting, small interfering RNA (siRNA) oligonucleotide in development for treatment of metabolic and vascular disease.
GSK will pay an upfront fee as well as potential future success-based development, regulatory and commercial milestones payments up to $1.005 billion, and tiered r…
